Adoptive transfer of CD8alpha+ dendritic cells (DC) isolated from mice infected with Chlamydia muridarum are more potent in inducing protective immunity than CD8alpha- DC.
Chlamydial infections are serious public health concerns worldwide. In this study, we examined the role of dendritic cell (DC) subsets in inducing protective immunity against chlamydial infection using an adoptive transfer approach. We found that CD11c+CD8alpha+ (double-positive, DP) DC, compared with CD11c+CD8alpha- (single-positive, SP) DC isolated from infected mice, are more potent inducers of protective immunity. Specifically, mice pretreated with DPDC from infected mice, upon infection with Chlamydia trachomatis mouse pneumonitis (MoPn), experienced significantly less severe body weight loss and in vivo chlamydial growth. Analysis of MoPn-driven cytokine production by immune cells revealed that mice that were treated with DPDC produced significantly higher levels of Th1 (TNF-alpha, IFN-gamma, and IL-12) but lower levels of Th2 (IL-4, IL-5, and IL-13)-related cytokines than the recipients of SPDC following infection challenge. Moreover, DPDC-treated mice displayed significantly higher levels of MoPn-specific IgG2a production and delayed-type hypersensitivity responses compared with SPDC-treated mice. Furthermore, DPDC isolated from infected mice produced higher amounts of IL-12 and IL-10 in vitro in comparison with SPDC. These data indicate that CD8alpha+ DC have a significantly higher capacity in inducing protective immunity compared with CD8alpha- DC, demonstrating the crucial role of DC1-like cells in eliciting protection against C. trachomatis infection.
Bilenki
Laura
L
Laboratory for Infection and Immunity, Departments of Immunology and Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Wang
Shuhe
S
Yang
Jie
J
Fan
Yijun
Y
Jiao
Lei
L
Joyee
Antony George
AG
Han
Xiaobing
X
Yang
Xi
X
D019264:Adoptive Transfer; D000818:Animals; D039521:CD11c Antigen / Q000096:biosynthesis; D016827:CD8 Antigens / Q000008:administration & dosage / Q000096:biosynthesis* / Q000276:immunology; D002469:Cell Separation; D002478:Cells, Cultured; D002690:Chlamydia Infections / Q000276:immunology* / Q000503:physiopathology / Q000517:prevention & control; D023502:Chlamydia muridarum / Q000254:growth & development / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology* / Q000382:microbiology / Q000637:transplantation*; D006367:HeLa Cells; D006801:Humans; D007110:Immunity, Active; D016130:Immunophenotyping; D051379:Mice; D008810:Mice, Inbred C57BL; D018410:Pneumonia, Bacterial / Q000276:immunology* / Q000503:physiopathology / Q000517:prevention & control; D018272:Porins / Q000276:immunology; D015431:Weight Loss / Q000276:immunology
D039521:CD11c Antigen; D016827:CD8 Antigens; C431698:CD8alpha antigen; D018272:Porins; C071677:omp1 protein, Chlamydia trachomatis